MA37645B1 - Formulations stabilisées contenant des anticorps anti-dll4 - Google Patents

Formulations stabilisées contenant des anticorps anti-dll4

Info

Publication number
MA37645B1
MA37645B1 MA37645A MA37645A MA37645B1 MA 37645 B1 MA37645 B1 MA 37645B1 MA 37645 A MA37645 A MA 37645A MA 37645 A MA37645 A MA 37645A MA 37645 B1 MA37645 B1 MA 37645B1
Authority
MA
Morocco
Prior art keywords
formulations containing
containing anti
antibody
dll4 antibodies
stabilized formulations
Prior art date
Application number
MA37645A
Other languages
English (en)
Other versions
MA37645A2 (fr
MA37645A3 (fr
Inventor
Scott Walsh
Daniel Dix
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48670784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37645(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA37645A2 publication Critical patent/MA37645A2/fr
Publication of MA37645A3 publication Critical patent/MA37645A3/fr
Publication of MA37645B1 publication Critical patent/MA37645B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

La présente invention concerne des formulations pharmaceutiques comprenant un anticorps qui se lie spécifiquement à un ligand humain delta-like 4 (dll4). Lesdites formulations peuvent contenir, outre un anticorps anti-dll4, un tampon de phosphate, un co-solvant organique, un disaccharide, et un sel. Les formulations pharmaceutiques selon la présente invention présentent un degré substantiel de stabilité d'anticorps après stockage pendant plusieurs mois et après avoir été soumises à une contrainte thermique et à d'autres contraintes physiques.
MA37645A 2012-05-31 2013-05-31 Formulations stabilisées contenant des anticorps anti-dll4 MA37645B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261653478P 2012-05-31 2012-05-31
PCT/US2013/043516 WO2013181486A1 (fr) 2012-05-31 2013-05-31 Formulations stabilisées contenant des anticorps anti-dll4

Publications (3)

Publication Number Publication Date
MA37645A2 MA37645A2 (fr) 2016-08-31
MA37645A3 MA37645A3 (fr) 2017-07-31
MA37645B1 true MA37645B1 (fr) 2018-10-31

Family

ID=48670784

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37645A MA37645B1 (fr) 2012-05-31 2013-05-31 Formulations stabilisées contenant des anticorps anti-dll4

Country Status (29)

Country Link
US (1) US9675692B2 (fr)
EP (1) EP2854849B1 (fr)
JP (1) JP6144758B2 (fr)
KR (1) KR20150033615A (fr)
CN (1) CN104349791A (fr)
AR (1) AR092325A1 (fr)
AU (1) AU2013267301B2 (fr)
BR (1) BR112014028997A2 (fr)
CA (1) CA2872275C (fr)
CL (1) CL2014003237A1 (fr)
CO (1) CO7151478A2 (fr)
DK (1) DK2854849T3 (fr)
EA (1) EA029779B1 (fr)
ES (1) ES2668900T3 (fr)
HK (1) HK1207305A1 (fr)
IL (1) IL235468A0 (fr)
LT (1) LT2854849T (fr)
MA (1) MA37645B1 (fr)
MX (1) MX357146B (fr)
NO (1) NO2887943T3 (fr)
NZ (1) NZ702288A (fr)
PH (1) PH12014502429B1 (fr)
PL (1) PL2854849T3 (fr)
PT (1) PT2854849T (fr)
SG (1) SG11201407171XA (fr)
SI (1) SI2854849T1 (fr)
TW (1) TWI609696B (fr)
UY (1) UY34842A (fr)
WO (1) WO2013181486A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2488204T3 (en) 2009-10-16 2016-06-06 Oncomed Pharm Inc Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents
US8858941B2 (en) 2011-09-23 2014-10-14 Oncomed Pharmaceuticals, Inc. VEGF/DLL4 binding agents and uses thereof
US20160176962A1 (en) 2014-10-31 2016-06-23 Oncomed Pharmaceuticals, Inc. Combination Therapy For Treatment Of Disease
US20180200325A1 (en) * 2014-11-18 2018-07-19 Shionogi & Co., Ltd. Stabilized peptide composition
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
BR112021015034A2 (pt) 2019-02-18 2021-10-05 Eli Lilly And Company Formulação de anticorpo terapêutico
CA3185091A1 (fr) * 2020-07-08 2022-01-13 Yuan Cheng Formulations stabilisees contenant des anticorps anti-ctla-4

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
US5016784A (en) 1990-02-15 1991-05-21 Dexus Research Inc. Applicator for highly reactive materials
WO1993000807A1 (fr) 1991-07-03 1993-01-21 Cryolife, Inc. Procede de stabilisation de biomateriaux
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0852951A1 (fr) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
DK0999853T3 (da) 1997-06-13 2003-04-22 Genentech Inc Stabiliseret antostofformulering
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
ES2644275T3 (es) 2000-08-11 2017-11-28 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen anticuerpos
US6875432B2 (en) 2000-10-12 2005-04-05 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
AU2003211991B2 (en) 2002-02-14 2008-08-21 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution formulations
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
PL1610820T5 (pl) 2003-04-04 2014-01-31 Genentech Inc Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
WO2005072772A1 (fr) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Compositions pharmaceutiques
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
PT1861116E (pt) 2005-03-25 2015-11-04 Regeneron Pharma Formulações de antagonista do vegf
EP1909831A4 (fr) 2005-06-14 2013-02-20 Amgen Inc Préparations de protéines à tamponnage spontané
CN101478949A (zh) 2006-06-16 2009-07-08 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
AU2007310838A1 (en) 2006-10-27 2008-05-02 Ablynx N.V. Intranasal delivery of polypeptides and proteins
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
RU2011140498A (ru) 2009-03-06 2013-04-20 Дженентек, Инк. Препарат антител
DK2488204T3 (en) * 2009-10-16 2016-06-06 Oncomed Pharm Inc Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents
MX2012005863A (es) 2009-11-20 2013-01-18 Centro Inmunologia Molecular Formulaciones de anticuerpos.
EP3680253A3 (fr) * 2010-03-02 2020-09-30 AbbVie Inc. Protéines de liaison dll4 thérapeutiques
PL2624865T3 (pl) * 2010-10-06 2018-11-30 Regeneron Pharmaceuticals, Inc. Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R)

Also Published As

Publication number Publication date
UY34842A (es) 2013-12-31
ES2668900T3 (es) 2018-05-23
DK2854849T3 (en) 2018-04-30
EP2854849B1 (fr) 2018-02-28
TW201400130A (zh) 2014-01-01
EA201492186A1 (ru) 2015-08-31
AU2013267301B2 (en) 2018-02-08
WO2013181486A1 (fr) 2013-12-05
HK1207305A1 (en) 2016-01-29
MA37645A2 (fr) 2016-08-31
EP2854849A1 (fr) 2015-04-08
EA029779B1 (ru) 2018-05-31
AU2013267301A1 (en) 2014-12-18
MX2014014363A (es) 2015-02-05
BR112014028997A2 (pt) 2017-07-25
US20130323260A1 (en) 2013-12-05
MX357146B (es) 2018-06-28
PT2854849T (pt) 2018-05-09
IL235468A0 (en) 2014-12-31
NZ702288A (en) 2016-12-23
KR20150033615A (ko) 2015-04-01
NO2887943T3 (fr) 2018-05-05
PL2854849T3 (pl) 2018-07-31
CA2872275C (fr) 2021-05-18
CN104349791A (zh) 2015-02-11
CL2014003237A1 (es) 2015-07-10
TWI609696B (zh) 2018-01-01
AR092325A1 (es) 2015-04-15
CO7151478A2 (es) 2014-12-29
JP2015520173A (ja) 2015-07-16
PH12014502429A1 (en) 2015-01-12
JP6144758B2 (ja) 2017-06-07
MA37645A3 (fr) 2017-07-31
US9675692B2 (en) 2017-06-13
LT2854849T (lt) 2018-05-10
SI2854849T1 (en) 2018-05-31
CA2872275A1 (fr) 2013-12-05
PH12014502429B1 (en) 2015-01-12
SG11201407171XA (en) 2014-11-27

Similar Documents

Publication Publication Date Title
MA37645A3 (fr) Formulations stabilisées contenant des anticorps anti-dll4
MA35904B1 (fr) Formulations stabilisées contenant des anticorps anti-ang2
Yewdell et al. Original antigenic sin: how original? How sinful?
MA33993B1 (fr) Formulations stabilisées contenant des anticorps contre le récepteur de l'interleukine-6 (il-6r)
MA35355B1 (fr) Formulations stabilisées contenant des anticorps anti-pcsk9
SG11201907321TA (en) Anti-gprc5d antibody and molecule comprising the antibody
JP2007520566A5 (fr)
TNSN07304A1 (en) Combination of xolair with immunosuppressive agent
MX2022014596A (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
MA35009B1 (fr) Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
CY1113003T1 (el) Ευσταθη παρασκευασματα laquinimod
IL194550A (en) Isolated antibodies or their fragments that bind to human protein tyrosine phosphate in a cell, their pharmaceutical preparations and their use
JO3449B1 (ar) صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
MX361668B (es) Formulación de anticuerpos.
EA200970469A1 (ru) Антитела-агонисты рецептора trkb и их применение
FR18C1032I2 (fr) Anticorps anti-fgf23 et composition pharmaceutique le comprenant
SA521430229B1 (ar) Il-33 صيغ ثابتة تحتوي على أجسام مضادة لـ
EA201070826A1 (ru) Антитела против pcrv
FR2912314B1 (fr) Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w.
MA31014B1 (fr) Vaccin contre la leishmania canine.
UA109148C2 (uk) Композиції на основі антитіла проти vegfr-3
BRPI0700133A (pt) composição farmacêutica compreendendo tramadol e cetoprofeno em combinação
Lee et al. Monoclonal Antibodies Attached to Carbon Nanotube Transistors for Paclitaxel Detection
TH154849A (th) สูตรตำรับที่บรรจุแอนติบอดีต้าน-dll4 ที่ถูกเพิ่มความคงตัว
TH92463A (th) สูตรผสมแอนติบอดีที่เสถียร